ZELTIQ to Present at the J.P. Morgan 34th Annual Healthcare Conference

PLEASANTON, CA -- (Marketwired) -- 12/18/15 -- ZELTIQ® (NASDAQ: ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced that Mark Foley, President and Chief Executive Officer is scheduled to present at the J.P. Morgan 34th Annual Healthcare Conference in San Francisco, CA. This conference will allow institutional investors to meet with the company following their formal presentation.

Event: J.P. Morgan 34th Annual Healthcare Conference

Date: Wednesday, January 13, 2016

Time: 7:30 a.m. PT / 10:30 a.m. ET

An audio webcast of the Company's presentation will be available by visiting the investor relations section of ZELTIQ's web site at www.coolsculpting.com. A replay of the presentation will be available for 90 days.

About ZELTIQ ® Aesthetics, Inc.

ZELTIQ is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. ZELTIQ's first commercial product, the CoolSculpting® System, is designed to selectively reduce stubborn fat bulges. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. It utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis. ZELTIQ developed CoolSculpting to safely, noticeably, and measurably reduce the fat layer.

   
    CONTACTS: 
    
    Investor Relations:Patrick F. WilliamsZELTIQSenior Vice President and CFO925-474-2500Nick LaudicoThe Ruth [email protected]

Source: ZELTIQ Aesthetics, Inc.

You May Also Be Interested In

• Rice's OpenStax awarded $90M to lead first-of-its-kind NSF research hub for transformational learning and education research
• The First Bancshares, Inc. Reports Results for First Quarter ended March 31, 2024
• GDRX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that GoodRx Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead the GoodRx Class Action Lawsuit